human MV833 monoclonal antibody
a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts
Also Known As:
MV833 monoclonal antibody, human; HuMV833; HuMV833 monoclonal antibody
Networked: 2
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Broughton, Lynn:
2 articles
(03/2005 - 10/2002)
|
| 2. | Groenewegen, Gerard:
2 articles
(03/2005 - 10/2002)
|
| 3. | Herold, Manfred:
2 articles
(03/2005 - 10/2002)
|
| 4. | Jackson, Alan:
2 articles
(03/2005 - 10/2002)
|
| 5. | Jayson, Gordon C:
2 articles
(03/2005 - 10/2002)
|
| 6. | Lawrance, Jeremy:
2 articles
(03/2005 - 10/2002)
|
| 7. | Lehmann, Frederic F:
2 articles
(03/2005 - 10/2002)
|
| 8. | Levitt, Dan:
2 articles
(03/2005 - 10/2002)
|
| 9. | Marreaud, Sandrine:
2 articles
(03/2005 - 10/2002)
|
| 10. | Mulatero, Clive:
2 articles
(03/2005 - 10/2002)
|
Related Diseases
| 1. | Neoplasms (Cancer)
10/02/2002
- " Because of the heterogeneity in tumor biology with respect to antibody uptake and clearance, we suggest that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with antiangiogenic compounds like HuMV833." 10/02/2002
- " Twenty patients with progressive solid tumors were treated with various doses of HuMV833 (0.3, 1, 3, or 10 mg/kg). " 10/02/2002
- " We developed HuMV833, a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts, and investigated the distribution and biologic effects of HuMV833 in patients in a phase I trial. " 03/01/2005
- " We assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth factor (VEGF) monoclonal antibody, HuMV833, in patients with advanced cancer. "
|
|
Related Drugs and Biologics